Innate Pharma (IPHA) — Free Cash Flow Generation Index

Latest as of June 2024: 0.91x

Innate Pharma (IPHA) has a Free Cash Flow Generation Index of 0.91x as of June 2024. Free cash flow of $2.75 Million represents 1% of operating cash flow ($3.04 Million). Explore IPHA capex reinvestment rate to see what proportion of operating cash flow is directed to capital expenditures.

FCF Generation Index

0.91x
Free Cash Flow / Operating CF

Free Cash Flow

$2.75 Million
USD

Operating Cash Flow

$3.04 Million
USD

Capital Expenditures

$283.00K
USD

Innate Pharma Free Cash Flow Generation Index (2006–2019)

Historical FCF Generation Index trend for Innate Pharma across 4 annual periods. For the full cash flow conversion analysis, see IPHA cash flow conversion.

Annual Free Cash Flow Generation for Innate Pharma (2006–2019)

Year-by-year Free Cash Flow Generation Index for Innate Pharma. Check Innate Pharma (IPHA) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Year FCG Index Free Cash Flow (USD) Operating CF Capital Expenditures YoY Change
2019 -0.87x $-30.48 Million $34.92 Million $65.40 Million ▼ -190.5%
2015 0.96x $200.51 Million $207.91 Million $7.40 Million ▼ -1.1%
2011 0.98x $12.66 Million $12.99 Million $322.00K ▲ +189.6%
2006 -1.09x $-392.00K $360.00K $752.00K
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).